HUAPONT PHARM.
INFORMATION CENTER
关于阿斯利康阿那曲唑相关专利无效的公告
2020-07-21 21:36
2019年4月阿斯利康向苏州市中级人民法院起诉华邦制药“侵害发明专利权纠纷”,提出我司产品阿那曲唑片(瑞婷)侵犯该公司第02824544.X号发明专利(阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途)。
VIEW MORE
Moxifloxacin was approved in Japan
2020-03-03 00:00
On February 10, 2020, Chongqing Huapont Pharmaceutical Co., Ltd. obtained the "Notice of Pharmaceutical Compliance Investigation Results" issued by the Japanese competent authority PMDA (Pharmaceuticals and Medical Devices Agency).
VIEW MORE
Huapont-Shimadzu Cooperative Laboratory Established
2019-09-10 00:00
As good cooperation between our company and Shimadzu Enterprise Management (China) Co., Ltd. for a long time , it is decided to jointly build a cooperative laboratory based on the needs of their future development strategies and to continually strengthen the cooperative relationship between the two parties.
VIEW MORE
Hi!
Thank you for visiting Huapont Pharma's official website, if you have any cooperation intentions or suggestions, please contact us through the following ways, we will contact with you as soon as possible, thank you!
Address: No. 69, Xingguang Avenue, Renhe Town, Yubei District, Chongqing, 401121, China.
Code: 401121
Email: service@huapont.cn
© 2024 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved.
渝公网安备 50019002503004号